← 返回

使用背包激活的中性粒细胞对胶质母细胞瘤进行免疫治疗

英文原题:Immunotherapy against glioblastoma using backpack-activated neutrophils.

查看英文原题

Immunotherapy against glioblastoma using backpack-activated neutrophils.

PubMed 2024/08/13(内容时间) Bioeng Transl Med Q1 · IF 6.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫检查点抑制剂(ICIs)是治疗多形性胶质母细胞瘤(GBM)的新兴治疗候选药物;然而,由于局部和全身免疫抑制环境,其疗效在临床上受到限制。

因此,刺激局部和全身免疫环境的治疗方法可以提高ICIs的疗效。在此,我们报道了一种采用中性粒细胞(NE)的过继细胞疗法,该中性粒细胞通过无药物圆盘状背包(称为细胞黏附微贴片,CAMPs)的表面附着而被激活,用于治疗GBM。附着CAMP的中性粒细胞(NE/CAMPs)在皮下小鼠GBM模型(GL261)中显著提高了抗PD1抗体(aPD-1)的疗效。NE/CAMPs与aPD-1的联合治疗使小鼠皮下GL261肿瘤完全消退。NE/CAMPs对GBM的疗效也在原位GL261模型中进行了测试。中性粒细胞迁移进入大脑的能力未受CAMP附着的影响,在荷原位GBM小鼠中观察到脑内NE/CAMP的积聚。在原位GBM模型中,NE/CAMPs与aPD-1的联合治疗激活了由T细胞介导的全身免疫反应,并显示出与单用aPD-1相比改善的治疗反应。这些结果表明,NE/CAMPs的免疫调节与ICIs联合为GBM的治疗提供了一种潜在方法。

展开英文摘要原文

Immune checkpoint inhibitors (ICIs) represent new therapeutic candidates against glioblastoma multiforme (GBM); however, their efficacy is clinically limited due to both local and systemic immunosuppressive environments. Hence, therapeutic approaches that stimulate local and systemic immune environments can improve the efficacy of ICIs.

Here, we report an adoptive cell therapy employing neutrophils (NE) that are activated via surface attachment of drug-free disk-shaped backpacks, termed Cyto-Adhesive Micro-Patches (CAMPs) for treating GBM. CAMP-adhered neutrophils (NE/CAMPs) significantly improved the efficacy of an anti-PD1 antibody (aPD-1) in a subcutaneous murine GBM model (GL261). A combination of NE/CAMPs and aPD-1 completely regressed subcutaneous GL261 tumors in mice. The efficacy of NE/CAMPs against GBM was also tested in an orthotopic GL261 model.

Neutrophil's ability to migrate into the brain was not affected by CAMP attachment, and intracerebral NE/CAMP accumulation was observed in mice-bearing orthotopic GBM. The combination treatment of NE/CAMPs and aPD-1 activated systemic immune responses mediated by T cells and showed improved therapeutic responses compared with aPD-1 alone in the orthotopic GBM model. These results suggest that immunomodulation with NE/CAMPs offers a potential approach for the treatment of GBM by combination with ICIs.

论文信息

作者
Fukuta T、Kumbhojkar N、Prakash S、Shaha S、Silva-Candal AD、Park KS、Mitragotri S
单位
Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University Boston Massachusetts USA.United States
期刊
Bioengineering & translational medicine2025 Jan
原文标识
PubMed 39801750 · DOI 10.1002/btm2.10712